344 related articles for article (PubMed ID: 16785502)
1. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice.
Knutson KL; Dang Y; Lu H; Lukas J; Almand B; Gad E; Azeke E; Disis ML
J Immunol; 2006 Jul; 177(1):84-91. PubMed ID: 16785502
[TBL] [Abstract][Full Text] [Related]
2. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
Nair RE; Kilinc MO; Jones SA; Egilmez NK
J Immunol; 2006 Jun; 176(12):7325-34. PubMed ID: 16751376
[TBL] [Abstract][Full Text] [Related]
3. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.
Gritzapis AD; Voutsas IF; Baxevanis CN
Cancer Immunol Immunother; 2012 Mar; 61(3):397-407. PubMed ID: 21928125
[TBL] [Abstract][Full Text] [Related]
4. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
[TBL] [Abstract][Full Text] [Related]
5. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity.
Jacob JB; Kong YC; Nalbantoglu I; Snower DP; Wei WZ
J Immunol; 2009 May; 182(9):5873-81. PubMed ID: 19380836
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells.
Brode S; Raine T; Zaccone P; Cooke A
J Immunol; 2006 Nov; 177(10):6603-12. PubMed ID: 17082572
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice.
Kurt RA; Whitaker R; Baher A; Seung S; Urba WJ
Int J Cancer; 2000 Sep; 87(5):688-94. PubMed ID: 10925363
[TBL] [Abstract][Full Text] [Related]
8. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity.
Onda M; Kobayashi K; Pastan I
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4575-4582. PubMed ID: 30760587
[TBL] [Abstract][Full Text] [Related]
9. Increased CD4+Foxp3+ T cells in BAFF-transgenic mice suppress T cell effector responses.
Walters S; Webster KE; Sutherland A; Gardam S; Groom J; Liuwantara D; Mariño E; Thaxton J; Weinberg A; Mackay F; Brink R; Sprent J; Grey ST
J Immunol; 2009 Jan; 182(2):793-801. PubMed ID: 19124722
[TBL] [Abstract][Full Text] [Related]
10. Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia.
Baba J; Watanabe S; Saida Y; Tanaka T; Miyabayashi T; Koshio J; Ichikawa K; Nozaki K; Koya T; Deguchi K; Tan C; Miura S; Tanaka H; Tanaka J; Kagamu H; Yoshizawa H; Nakata K; Narita I
Blood; 2012 Sep; 120(12):2417-27. PubMed ID: 22806892
[TBL] [Abstract][Full Text] [Related]
11. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
[TBL] [Abstract][Full Text] [Related]
12. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo.
Wu T; Zhang L; Xu K; Sun C; Lei T; Peng J; Liu G; Wang R; Zhao Y
Transpl Immunol; 2012 Aug; 27(1):30-8. PubMed ID: 22613676
[TBL] [Abstract][Full Text] [Related]
14. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites.
Chaput N; Darrasse-Jèze G; Bergot AS; Cordier C; Ngo-Abdalla S; Klatzmann D; Azogui O
J Immunol; 2007 Oct; 179(8):4969-78. PubMed ID: 17911581
[TBL] [Abstract][Full Text] [Related]
16. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells.
Weiss VL; Lee TH; Song H; Kouo TS; Black CM; Sgouros G; Jaffee EM; Armstrong TD
PLoS One; 2012; 7(2):e31962. PubMed ID: 22359647
[TBL] [Abstract][Full Text] [Related]
17. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
18. Elevated T regulatory cells in long-term stable transplant tolerance in rhesus macaques induced by anti-CD3 immunotoxin and deoxyspergualin.
Asiedu CK; Goodwin KJ; Balgansuren G; Jenkins SM; Le Bas-Bernardet S; Jargal U; Neville DM; Thomas JM
J Immunol; 2005 Dec; 175(12):8060-8. PubMed ID: 16339543
[TBL] [Abstract][Full Text] [Related]
19. Critical role of regulatory T cells in Th17-mediated minor antigen-disparate rejection.
Vokaer B; Van Rompaey N; Lemaître PH; Lhommé F; Kubjak C; Benghiat FS; Iwakura Y; Petein M; Field KA; Goldman M; Le Moine A; Charbonnier LM
J Immunol; 2010 Sep; 185(6):3417-25. PubMed ID: 20733201
[TBL] [Abstract][Full Text] [Related]
20. The Critical Role of Induced CD4+ FoxP3+ Regulatory Cells in Suppression of Interleukin-17 Production and Attenuation of Mouse Orthotopic Lung Allograft Rejection.
Zhou W; Zhou X; Gaowa S; Meng Q; Zhan Z; Liu J; Li J; Fan H; Liu Z
Transplantation; 2015 Jul; 99(7):1356-64. PubMed ID: 25856405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
